Loading...
•
Sep 30, 2022
Collegium Q3 2022 Earnings Report
Generated record net revenue and completed Xtampza ER contract renegotiations.
Key Takeaways
Collegium Pharmaceutical, Inc. reported a record net revenue of $127.0 million for Q3 2022. The company completed Xtampza® ER contract renegotiations and returned $10M in capital to shareholders through share repurchases. They also updated their full year 2022 guidance.
Generated record net revenue of $127.0 million
Completed Xtampza ER contract renegotiations, confirmed Xtampza ER gross-to-net will be less than 65% beginning January 2023
Returned $10M in capital to shareholders through share repurchases
Updated full year 2022 guidance
Forward Guidance
The Company updates its full-year 2022 guidance for Total Product Revenues, Total Adjusted Operating Expenses, and Total Adjusted EBITDA
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...